CANCER CENTER SUPPORT GRANT

癌症中心支持补助金

• 批准号: 3101714
• 负责人: JAMES F HOLLAND
• 金额: $ 76.68万
• 依托单位: MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-07-01 至 1987-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3101714
• 关键词: biomedical facility

The Specialized Cancer Center at Mount Sinai School of Medicine continues its work in immunologic diagnosis of breast cancer, analytical chemical diagnosis of fungal and bacterial infection and pathologic diagnosis of cells of interest by electronmicroscopy characteristics. Pharmacology of human cell lines in vitro in their native state and in the induced resistance state are conducted. Major emphasis has been placed on folic acid antagonists resistance and 2.4. diamminopyridine collateral sensitivity. Drug testing on human mesothelioma explanted into athymic mice continues. Investigation of electromagnetic radiation on chemotherapeutic effect on animal tumors is in progress. Clinical pharmacology of citrovorum and its modulation of 5-fluorouracil chemotherapeutic activity has begun. Controlled comparisons of cisplatin and doxorubicin versus cisplatin, doxorubicin and cyclophosphamide in ovarian cancer is in progress. A new trial comparing methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) versus MEPH (mitocycin, etoposide, cisplatin and hexamethylmelamine) followed by MACC offers a new lead in lung cancer, since MEPH has been recognized to demonstrate activity even after MACC failure. Studies of chemotherapy in an adjuvant setting of breast cancer and of colon cancer continues. Exploratory techniques of treating brain tumors have begun. Mathematical modeling of anticipated outcome has been progressively used to design regimens worthy of clinical tests. Such regimens, pioneered in the Cancer Center, have been extrapolated to Cooperative Study Groups for further implementation. The organizaion and interrelationships within the Cancer Center have significantly improved this past year, and a more cohesive effort across the entire Medical School is now evident. This application is submitted for continued support of the administration of the Cancer Center.

西奈山医学院的专门癌症中心继续 从事乳腺癌免疫学诊断的工作，分析化学诊断 真菌和细菌感染以及对感兴趣细胞的病理诊断 电子显微镜特征。 体外人细胞系的药理学 在其本地状态和诱导的抗性状态下进行。 主要的 重点已放在叶酸拮抗剂耐药性和2.4上。 二氨基吡啶的侧支敏感性。 人间皮瘤的药物测试 远洋小鼠的外观仍在继续。 电磁研究 对动物肿瘤的化学治疗作用的辐射正在进行中。 临床 柑橘类药理学及其对5-氟尿嘧啶化学治疗的调节 活动已经开始。 顺铂和阿霉素的受控比较与 卵巢癌中的顺铂，阿霉素和环磷酰胺正在进行。 一个 比较甲氨蝶呤，阿霉素，环磷酰胺和CCNU（MACC）的新试验 vers meph（线粒体，依托泊苷，顺铂和己酰胺），然后是 MACC为肺癌提供了新的铅，因为Meph已被认可 即使在MACC失败之后也表现出活动。 化学疗法的研究 乳腺癌和结肠癌的辅助设置仍在继续。 探索性 治疗脑肿瘤的技术已经开始。 数学建模 预期的结果已逐渐被用来设计值得 临床测试。 在癌症中心开创的这种方案已经 推断到合作研究小组进行进一步实施。 癌症中心内的组织和相互关系 过去一年有了显着改善，并且在整个 整个医学院现在都很明显。 此申请提交 继续支持癌症中心的管理。